141 related articles for article (PubMed ID: 35740649)
1. Bone Marrow Fibrosis at Diagnosis and during the Course of Disease Is Associated with TP53 Mutations and Adverse Prognosis in Primary Myelodysplastic Syndrome.
Zhao Y; Guo J; Zhao S; Wang R; Shi L; Fang Y; Zhang Z; Song L; Wu D; Chang C
Cancers (Basel); 2022 Jun; 14(12):. PubMed ID: 35740649
[TBL] [Abstract][Full Text] [Related]
2. Fibrosis identified in the bone marrow biopsies of patients with essential thrombocythemia: its incidence and significance for the differential diagnostic considerations.
Marcinek J; Plank L; Szépe P; Balhárek T
Cesk Patol; 2008 Jul; 44(3):62-6. PubMed ID: 18783136
[TBL] [Abstract][Full Text] [Related]
3. Bone marrow fibrosis in chronic myelomonocytic leukemia is associated with increased megakaryopoiesis, splenomegaly and with a shorter median time to disease progression.
Petrova-Drus K; Chiu A; Margolskee E; Barouk-Fox S; Geyer J; Dogan A; Orazi A
Oncotarget; 2017 Nov; 8(61):103274-103282. PubMed ID: 29262560
[TBL] [Abstract][Full Text] [Related]
4. TP53 overexpression is an independent adverse prognostic factor in de novo myelodysplastic syndromes with fibrosis.
Loghavi S; Al-Ibraheemi A; Zuo Z; Garcia-Manero G; Yabe M; Wang SA; Kantarjian HM; Yin CC; Miranda RN; Luthra R; Medeiros LJ; Bueso-Ramos CE; Khoury JD
Br J Haematol; 2015 Oct; 171(1):91-9. PubMed ID: 26123119
[TBL] [Abstract][Full Text] [Related]
5. The clinical importance of moderate/severe bone marrow fibrosis in patients with therapy-related myelodysplastic syndromes.
Fu B; Ok CY; Goswami M; Xei W; Jaso JM; Muzzafar T; Bueso-Ramos C; Verstovsek S; Garcia-Manero G; Medeiros LJ; Wang SA
Ann Hematol; 2013 Oct; 92(10):1335-43. PubMed ID: 23660629
[TBL] [Abstract][Full Text] [Related]
6. Decoding Bone Marrow Fibrosis in Myelodysplastic Syndromes.
Melody M; Al Ali N; Zhang L; Ramadan H; Padron E; Sallman D; Sweet K; Lancet J; List A; Bennett JM; Komrokji R
Clin Lymphoma Myeloma Leuk; 2020 May; 20(5):324-328. PubMed ID: 32044274
[TBL] [Abstract][Full Text] [Related]
7. [Features and clinical significance of gene mutations in patients with myelodysplastic syndromes with ring sideroblasts].
Cai YN; Xu ZF; Li B; Qin TJ; Pan LJ; Qu SQ; Hu NB; Liu D; Huang HJ; Shi ZX; Zhang YD; Xiao ZJ
Zhonghua Xue Ye Xue Za Zhi; 2020 May; 41(5):379-386. PubMed ID: 32536134
[No Abstract] [Full Text] [Related]
8. Genomic context and TP53 allele frequency define clinical outcomes in TP53-mutated myelodysplastic syndromes.
Montalban-Bravo G; Kanagal-Shamanna R; Benton CB; Class CA; Chien KS; Sasaki K; Naqvi K; Alvarado Y; Kadia TM; Ravandi F; Daver N; Takahashi K; Jabbour E; Borthakur G; Pemmaraju N; Konopleva M; Soltysiak KA; Pierce SR; Bueso-Ramos CE; Patel KP; Kantarjian H; Garcia-Manero G
Blood Adv; 2020 Feb; 4(3):482-495. PubMed ID: 32027746
[TBL] [Abstract][Full Text] [Related]
9. TP53 mutations are associated with very complex karyotype and suggest poor prognosis in newly diagnosed myelodysplastic syndrome patients with monosomal karyotype.
Ren Y; Wang J; Zhang H; Mei C; Ye L; Luo Y; Zhou X; Zhu S; Jiang L; Wang L; Jin J; Tong H
Asia Pac J Clin Oncol; 2020 Jun; 16(3):172-179. PubMed ID: 32030889
[TBL] [Abstract][Full Text] [Related]
10. Distinct mutation profile and prognostic relevance in patients with hypoplastic myelodysplastic syndromes (h-MDS).
Yao CY; Hou HA; Lin TY; Lin CC; Chou WC; Tseng MH; Chiang YC; Liu MC; Liu CW; Kuo YY; Wu SJ; Liao XW; Lin CT; Ko BS; Chen CY; Hsu SC; Li CC; Huang SY; Yao M; Tang JL; Tsay W; Liu CY; Tien HF
Oncotarget; 2016 Sep; 7(39):63177-63188. PubMed ID: 27527853
[TBL] [Abstract][Full Text] [Related]
11. TP53 mutations in myelodysplastic syndrome are strongly correlated with aberrations of chromosome 5, and correlate with adverse prognosis.
Kulasekararaj AG; Smith AE; Mian SA; Mohamedali AM; Krishnamurthy P; Lea NC; Gäken J; Pennaneach C; Ireland R; Czepulkowski B; Pomplun S; Marsh JC; Mufti GJ
Br J Haematol; 2013 Mar; 160(5):660-72. PubMed ID: 23297687
[TBL] [Abstract][Full Text] [Related]
12. [Analysis of clinical features and prognosis of primary myelodysplastic syndromes with myelofibrosis patients].
Su T; Zhang PH; Xu ZF; Chen HS; Qin TJ; Zhang Y; Zhang HL; Fan LW; Pan LJ; Xiao ZJ
Zhonghua Xue Ye Xue Za Zhi; 2012 May; 33(5):378-82. PubMed ID: 22781796
[TBL] [Abstract][Full Text] [Related]
13. [Mean corpuscular volume ≤100 fl was an independent prognostic factor in patients with myelodysplastic syndrome and bone marrow blast<5 percent].
Shi ZX; Qin TJ; Xu ZF; Huang HJ; Li B; Qu SQ; Hu NB; Pan LJ; Liu D; Cai YN; Zhang YD; Xiao ZJ
Zhonghua Xue Ye Xue Za Zhi; 2020 Jan; 41(1):28-33. PubMed ID: 32023751
[No Abstract] [Full Text] [Related]
14. Bone marrow fibrosis in myelodysplastic syndromes: a prospective evaluation including mutational analysis.
Ramos F; Robledo C; Izquierdo-García FM; Suárez-Vilela D; Benito R; Fuertes M; Insunza A; Barragán E; Del Rey M; García-Ruiz de Morales JM; Tormo M; Salido E; Zamora L; Pedro C; Sánchez-Del-Real J; Díez-Campelo M; Del Cañizo C; Sanz GF; Hernández-Rivas JM;
Oncotarget; 2016 May; 7(21):30492-503. PubMed ID: 27127180
[TBL] [Abstract][Full Text] [Related]
15. [Analysis of mutations of 14 genes among 87 patients with myelodysplastic syndrome].
Zhou X; Jin H; Mu Q; Sheng L; Lai B; Zhu H; Ouyang G
Zhonghua Yi Xue Yi Chuan Xue Za Zhi; 2019 Oct; 36(10):953-956. PubMed ID: 31598934
[TBL] [Abstract][Full Text] [Related]
16. Patients of Myelodysplastic Syndrome with Mild/Moderate Myelofibrosis and a Monosomal Karyotype are Independently Associated with an Adverse Prognosis: Long-Term Follow-Up Data.
Wang N; Xu H; Li Q; Fang X; Liu J; Sui X; Zhang L; Jiang Y; Wang X
Cancer Manag Res; 2020; 12():5881-5891. PubMed ID: 32765089
[TBL] [Abstract][Full Text] [Related]
17. [Clinical Characteristics and Karyotype Analysis of Myelodysplastic Syndrome Patients with TP53 mutation].
Zhou XY; Ouyang GF; Mu QT; Sheng LX
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2019 Jun; 27(3):872-876. PubMed ID: 31204947
[TBL] [Abstract][Full Text] [Related]
18. Inflammation-related genes S100s, RNASE3, and CYBB and risk of leukemic transformation in patients with myelodysplastic syndrome with myelofibrosis.
Hong M; Wu J; Ma L; Han X; Lu T; Wang Z; Zhao J; Liu L; Fu H; Huang W; Zheng W; He J; Wei G; Wang H; Chen Z; Huang H; Cai Z; Guo G; Sun J
Biomark Res; 2021 Jul; 9(1):53. PubMed ID: 34229751
[TBL] [Abstract][Full Text] [Related]
19. Integration Analysis of
Fang Y; Guo J; Wu D; Wu LY; Song LX; Zhang Z; Zhao YS; Chang CK
Front Oncol; 2020; 10():610525. PubMed ID: 33520721
[TBL] [Abstract][Full Text] [Related]
20. Targeted next-generation sequencing in myelodysplastic syndromes and prognostic interaction between mutations and IPSS-R.
Tefferi A; Lasho TL; Patnaik MM; Saeed L; Mudireddy M; Idossa D; Finke C; Ketterling RP; Pardanani A; Gangat N
Am J Hematol; 2017 Dec; 92(12):1311-1317. PubMed ID: 28875545
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
